Regulatory Focus™ > News Articles > Nanomedicine: Prospects, Risks and Regulatory Issues

Nanomedicine: Prospects, Risks and Regulatory Issues

Posted 01 December 2011 | By

Doxil, Ontak and Abraxane are all US Food and Drug Administration (FDA) approved nanoparticle (NP) drug delivery systems for cancer indications.1,2 The dynamic development of cancer nanotechnology is in line with the position of the National Cancer Institute (NCI), which has recognized nanotechnology as an unprecedented opportunity to study normal and cancer cells in real time at the molecular scale and during the earliest stage of cancer progression.3

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe